Aktis Oncology, Inc.
Financials
Valuation Metrics
Aktis Oncology, Inc.'s Market Cap is $806M. Ranked #2463 of 3,116 in US market (top 79%), #1013 of 1,472 on NASDAQ (top 69%), #184 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 69%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $806M | US#2,463/3,116 Sec#184/265 |
| Revenue | $10M | US#2,805/3,116 Sec#169/265 |
| Net Income | $-73M | US—/3,116 Sec—/265 |
| Total Assets | $558M | US#2,719/3,116 Sec#151/265 |
| Net Assets | $485M | US#2,239/3,116 Sec#110/265 |
| Employees | 79 | US#2,650/3,116 Sec#190/265 |
| Value | ||
| P/B | 1.66x | US#1,203/3,116 Sec#53/265 |
| P/S | 80.11x | US#2,938/3,116 Sec#177/265 |
| FCF Yield | -10.49% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -15.09% | US#2,421/3,116 Sec#90/265 |
| ROA | -13.12% | US#2,707/3,116 Sec#111/265 |
| Op. Margin | -866.63% | US#2,800/3,116 Sec#163/265 |
| Revenue Growth | 336.92% | US#37/3,116 Sec#16/265 |
| Financial Health | ||
| Debt Ratio | 15.01% | US#171/3,116 Sec#68/265 |
| Total Debt | $11M | US#2,816/3,116 Sec#196/265 |
| FCF | $-85M | US#2,609/3,116 Sec#134/265 |
| Cash | $82M | US#2,332/3,116 Sec#187/265 |
| Current Ratio | 16.33x | US#145/3,116 Sec#41/265 |
| Performance | ||
| 1M Return | -21.27% | US#2,732/3,116 Sec#216/265 |
| From 52W High | -57.36% | US#2,675/3,116 Sec#203/265 |
| 1Y MDD | -54.76% | US#2,522/3,116 Sec#181/265 |
| Trading | ||
| Volume | 854,445 shares | US#2,560/3,116 Sec#242/265 |
| Trading Value | $13M | US#2,712/3,116 Sec#221/265 |
| Per Share | ||
| EPS | $-1.32 | US—/3,116 Sec—/265 |
| BPS | $8.77 | US#1,920/3,116 Sec#78/265 |
Company Info
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.